Dexa Laboratories Of Biomolecular Science Report issue

For profit Phase 3
Founded: West Java Indonesia (1969)

Organization Overview

First Clinical Trial
2020
NCT04425590
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Dexa Laboratories Of Biomolecular Science

Active Ingredients

Drugs in Phase 3 Trials (3)

acetylsalicylic acid (aspirin) (1 trial)

cobalamin (1 trial)

Lumbricus rubellus (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 3)

Ischemia (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3